Voyager Therapeutics initiated with a Buy at Citi

Citi initiated coverage of Voyager Therapeutics (VYGR) with a Buy rating and $12 price target Voyager is an early clinical-staged biotech developing therapies for the treatment of neurological disorders, the analyst tells investors in a research note. The firm sees “meaningful value” in Voyager’s platform from both a clinical and business development perspective. The company’s anti-tau antibody, VY7523, is currently in a Phase 1a for healthy volunteers with data expected in the first half of 2025, Citi points out.